 Proprotein Convertase 9
"Proprotein Convertase 9" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A proprotein convertase that is essential for CHOLESTEROL homeostasis. It binds to and is required for the lysosomal degradation of the LDL RECEPTOR (LDLR); the VLDL receptor, and the APOLIPOPROTEIN E RECEPTOR. It also regulates neuronal APOPTOSIS.
| Descriptor ID |
D000071449
|
| MeSH Number(s) |
D08.811.277.656.300.760.718 D08.811.277.656.837.688 D08.811.277.656.959.350.718
|
| Concept/Terms |
Proprotein Convertase 9- Proprotein Convertase 9
- Convertase 9, Proprotein
- Neural Apoptosis-Regulated Convertase 1
- Neural Apoptosis Regulated Convertase 1
- NARC-1 Protein
- NARC 1 Protein
- Proprotein Convertase, Subtilisin-Kexin Type 9
- Proprotein Convertase, Subtilisin Kexin Type 9
|
Below are MeSH descriptors whose meaning is more general than "Proprotein Convertase 9".
Below are MeSH descriptors whose meaning is more specific than "Proprotein Convertase 9".
This graph shows the total number of publications written about "Proprotein Convertase 9" by people in this website by year, and whether "Proprotein Convertase 9" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2014 | 0 | 2 | 2 | | 2016 | 1 | 1 | 2 | | 2017 | 2 | 1 | 3 | | 2018 | 0 | 4 | 4 | | 2019 | 4 | 4 | 8 | | 2020 | 2 | 8 | 10 | | 2021 | 3 | 5 | 8 | | 2022 | 1 | 5 | 6 | | 2023 | 0 | 8 | 8 | | 2024 | 1 | 3 | 4 | | 2025 | 0 | 4 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Proprotein Convertase 9" by people in Profiles.
-
Singh K, Foster MW, Violette MJ, Corcoran AM, Hotchkiss KM, Railton CO, Blandford EE, Blethen KE, Thomas EL, McIntosh WC, Ashley DM, Desjardins A, Friedman HS, Johnson MO, Friedman A, Keir S, Buckley ED, Herndon JE, McLendon RE, Sampson JH, Calabrese E, López GY, Grant GA, Patel AP, Gregory SG, Li CY, Fecci PE, Khasraw M. A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma. Sci Rep. 2025 Oct 23; 15(1):37112.
-
Myerson M, Warden BA, Saseen JJ, Paparodis R. Challenges in the Choice of Nonstatin Medications for Low-Density Lipoprotein-C Lowering for Cardiovascular Risk Reduction. J Am Heart Assoc. 2025 Oct 21; 14(20):e044134.
-
Reijnders E, Bossuyt PM, Jukema JW, Ruhaak LR, Romijn FPHTM, Szarek M, Trompet S, Bhatt DL, Bittner VA, Diaz R, Fazio S, Stevanovic I, Goodman SG, Harrington RA, White HD, Steg PG, Schwartz GG, Cobbaert CM. Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy. Arterioscler Thromb Vasc Biol. 2025 Nov; 45(11):2111-2123.
-
Geba GP, Mohammadi KA, Damask A, Paulding C, Lotta LA, Hindy G, Pordy R, Manvelian G, Shapiro MD, Bittner VA, Bhatt DL, Szarek M, Schwartz GG, Steg PG, Fazio S. Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial. J Am Heart Assoc. 2025 Sep 02; 14(17):e041190.
-
Grosche P, Flyer AN, Gattlen R, Xu M, Golosov AA, Vera V, Pickett S, Brousseau ME, Chopra R, Clairmont KB, Koch A, Liu E, Reid P, Perry L, Yang L, Yang Q, Monovich LG. Discovery of Truncated Cyclic Peptides Targeting an Induced-Fit Pocket on PCSK9. ChemMedChem. 2024 Dec 02; 19(23):e202400208.
-
Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, Lesogor A, Maheux P, Talloczy Z, Zang X, Schwartz GG, Ray KK. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024 10 14; 120(12):1400-1410.
-
Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Harrington RA, Jukema JW, White HD, Zeiher AM, Manvelian G, Pordy R, Poulouin Y, Stipek W, Garon G, Schwartz GG. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16; 10(4):342-352.
-
Ray KK, Gunn LH, Conde LG, Raal FJ, Wright RS, Gosselin NH, Leiter LA, Koenig W, Schwartz GG, Landmesser U. Estimating potential cardiovascular health benefits of improved population level control of LDL cholesterol through a twice-yearly siRNA-based approach: A simulation study of a health-system level intervention. Atherosclerosis. 2024 04; 391:117472.
-
Wright RS, Koenig W, Landmesser U, Leiter LA, Raal FJ, Schwartz GG, Lesogor A, Maheux P, Stratz C, Zang X, Ray KK. Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7 Clinical Trials. J Am Coll Cardiol. 2023 12 12; 82(24):2251-2261.
-
Landmesser U, Koenig W, Leiter LA, Raal FJ, Ray KK, Wright RS, Han J, Conde LG, Schwartz GG. Inclisiran in patients with prior myocardial infarction: A post hoc pooled analysis of the ORION-10 and ORION-11 Phase 3 randomised trials. Atherosclerosis. 2023 12; 386:117354.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|